Ciprofloxacin immunomodulation of experimental antiphospholipid syndrome associated with elevation of interleukin-3 and granulocyte-macrophage colony- stimulating factor expression

Arthritis and Rheumatism

Volumn 41, Issue 2, 1998, Pages 224-232

  Blank, Miri ^a,b   George, Jacob ^a,b   Fishman, Pnina ^b   Levy, Yair ^a,b   Toder, Vladimir ^b   Savion, Shoshana ^b   Barak, Vivian ^c   Koike, Takao ^d   Shoenfeld, Yehuda ^a,b  

^a SHEBA MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

^c HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^d HOKKAIDO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CEFTAZIDIME; CIPROFLOXACIN; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 3; MESSENGER RNA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY TITER; ANTIPHOSPHOLIPID SYNDROME; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG MECHANISM; FETUS WASTAGE; IMMUNOMODULATION; INTRAPERITONEAL DRUG ADMINISTRATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; SPLEEN CELL; THROMBOCYTOPENIA;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTI-INFECTIVE AGENTS; ANTIBODY FORMATION; ANTIPHOSPHOLIPID SYNDROME; BONE MARROW; CEFTAZIDIME; CELL COUNT; CIPROFLOXACIN; COLONY-FORMING UNITS ASSAY; FEMALE; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; INTERLEUKIN-3; MEGAKARYOCYTES; MICE; MICE, INBRED BALB C; PREGNANCY; SPLEEN;

EID: 0031935283     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/1529-0131(199802)41:2<224::AID-ART6>3.0.CO;2-W     Document Type: Article

References (57)

1. Harris EN, Gharavi AE, Boey ML, Patel BM, Mackworth-Young CG, Loizou S, et al. Anticardiolipin antibodies: detection by radioimmunoassay and association with thrombosis in systemic lupus erythematosus. Lancet 1983;2:1211-4.
2. Asherson RA. A "primary" anti-phospholipid syndrome. J Rheumatol 1989;15:1742-6.
3. Alarcón-Segovia D, Sanchez-Guerrero J. Primary antiphospholipid syndrome. J Rheumatol 1986;16:482-8.
4. Hughes GRV, Harris EN, Gharavi AE. The anti-cardiolipin syndrome. J Rheumatol 1986;13:486-8.
5. Lockshin MD. Anticardiolipin antibody. Arthritis Rheum 1987;30: 471-2.
6. Khamashta MA, Harris EN, Gharavi AE, Derue G, Gil A, Vazquez J, et al. Immune mediated mechanism for thrombosis: anti-phospholipid antibody binding to platelet membrane. Ann Rheum Dis 1988;47:849-54.
7. Roubey RAS. Immunology of the antiphospholipid antibody syndrome. Arthritis Rheum 1996;39:1444-54.
8. McNeil HP, Chesterman CN, Krilis SA. Immunological and clinical importance of anti-phospholipid antibodies. Adv Immunol 1991;49:193-280.
9. Harris EN, Asherson RA, Gharavi AE. Thrombocytopenia in SLE and related autoimmune disorders association with anticardiolipin antibody. Br J Haematol 1985;59:227-303.
10. 2-glycoprotein I and clinical manifestations in patients with systemic lupus erythematosus. Arthritis Rheum 1996;39:1466-74.
11. Sletnes KE, Smith P, Abdelnoor M, Arneson H, Wistoff F. Antiphospholipid antibodies after myocardial infarct and their relation to mortality, reinfarction, and nonhaemorrhagic stroke. Lancet 1992;339:451-3.
12. Triplett DA. Anti-phospholipid antibodies and thrombosis: a consequence, coincidence, or cause? Arch Pathol Lab Med 1993; 117:78-88.
13. Vaarala O, Palosuo T, Kleemola M, Ans A. Anticardiolipin response in acute infections. Clin Immunol Immunopathol 1986; 41:8-15.
14. Hojnik M, Guilbrud B, Ziporen L, Blank M, Tomer Y, Scheinberg MA, et al. Anti-cardiolipin antibodies in infections are heterogeneous in their dependency on beta-2-glycoprotein; analysis of anticardiolipin antibodies in leprosy. Lupus 1986;3:515-21.
15. Asherson RA, Mercey D, Phillips G, Sheehan N, Gharavi AE, Harris EN, et al. Recurrent stroke and multi-infarct dementia in systemic lupus erythematosus: association with antiphospholipid antibodies. Ann Rheum Dis 1987;46:605-11.
16. Blank M, Cohen J, Toder V, Shoenfeld Y. Induction of antiphospholipid syndrome by passive transfer of anticardiolipin antibodies. Proc Natl Acad Sci U S A 1991;88:3069-73.
17. Bakimer R, Fishman P, Blank M, Sredni B, Djaldetti M, Shoenfeld Y. Induction of primary anti-phospholipid syndrome in mice by immunization with a human monoclonal anti-cardiolipin antibody (H-3). J Clin Invest 1992;89:1558-63.
18. Blank M, Krause I, Ben-Bassat M, Shoenfeld Y. Induction of experimental anti-phospholipid syndrome associated with SLE following immunization with human monoclonal pathogenic anti-DNA idiotype. J Autoimmun 1992;5:495-509.
19. Cohen J, Bakimer R, Blank M, Valesini G, Shoenfeld Y. Pathogenic natural anti-cardiolipin antibodies: the experience from monoclonal gammopathy. Clin Exp Immunol 1994;97:181-6.
20. Branch DW, Dudley DJ, Mitchell MD, Creighton KA, Abott TM, Hammond E, et al. Immunoglobulin G fractions from patients with anti-phospholipid antibodies cause fetal death in BALBA/c mice: a model for autoimmune fetal loss. Am J Obstet Gynecol 1990;163:210-6.
21. Pierangeli SS, Harris EN. Induction of phospholipid-binding antibodies in mice and rabbits by immunization with human β-2-glycoprotein 1 or anticardiolipin antibodies alone. Clin Exp Immunol 1993;93:269-72.
22. Suzuki T, Takabayashi K, Ichikawa K, Ishiguro IN, Yoshiki T, Koike T. Effect of monoclonal anticardiolipin antibody on pregnant mice. J Rheumatol 1996;23:83-6.
23. Pierangeli SS, Xiao W, Lui W, Anderson G, Baker JH, Harris EN. Thrombotogenic properties of murine anti-cardiolipin antibodies induced by beta-2-glycoprotein I and human immunoglobulin G anti-phospholipid antibodies. Circulation 1996;1746-51.
24. Krause I, Blank M, Guilbrud B, Shoenfeld Y. The effect of aspirin on recurrent fetal loss in experimental anti-phospholipid syndrome. Am J Reprod Immunol 1993;29:155-61.
25. Inbar O, Blank M, Faden D, Tincani A, Lorber M, Shoenfeld Y. Prevention of fetal loss in experimental anti-phospholipid syndrome by low molecular weight heparin. Am J Reprod Immunol 1993;169:423-6.
26. Fishman P, Bakimer R, Blank M, Sredni D, Djaldetti M, Shoenfeld Y. The putative role of cytokines in the induction of primary anti-phospholipid syndrome. Clin Exp Immunol 1992;90:266-70.
27. Bakimer R, Gilbrud B, Zurgil N, Shoenfeld Y. The effect of intravenous gamma-globulin (IVGG) on the induction of experimental anti-phospholipid syndrome. Clin Immunol Immunopathol 1993;69:97-102.
28. Fishman P, Falach-Vaknin E, Zigelman R, Bakimer R, Sredni B, Djaldetti M, et al. Prevention of fetal loss in experimental antiphospholipid syndrome by in vivo administration of recombinant interleukin-3. J Clin Invest 1993;91:1834-7.
29. Fishman P, Falach-Vaknin E, Sredni B, Meroni PL, Rudniki C, Shoenfeld Y. Aspirin modulates interleukin-3 production: additional explanation for the preventive effects of aspirin in antiphospholipid antibody syndrome. J Reumatol 1995;22:1086-90.
30. Blank M, Krause I, Buskila D, Teitelbaum D, Kopolovic J, Afek A, et al. Bromocriptine immunomodulation of experimental SLE and primary anti-phospholipid syndrome via induction of nonspecific T suppressor cells. Cell Immunol 1995;162:114-22.
31. Blank M, Tomer Y, Slavin S, Shoenfeld Y. Induction of tolerance to experimental anti-phospholipid syndrome (APS) by syngeneic bone marrow cell transplantation. Scand J Immunol 1995;42:226-34.
32. Krause I, Blank M, Kopolovic J, Afek A, Goldberg I, Tomer Y, et al. Abrogation of experimental systemic lupus erythematosus and primary antiphospholipid syndrome with intravenous gamma globulin. J Rheumatol 1995;22:1068-74.
33. Guenounou M, Ronco E, Kodari E, Vacheron F, Momrikof V. Modulation by quinolones of the in vitro proliferative response of splenic cells of the mouse and IL-1 production. Pathol Biol 1987;35:785-9.
34. Roche Y, Fay M, Gougerol-Pocidalo MA. Enhancement of interleukin 2 production by quinolone-treated human mononuclear leukocytes. Int Immunopharmacol 1988;10:161-7.
35. Riesbeck K, Andersson J, Gullberg M, Forsgren A. Fluorinated 4-quinolones induce hyperproduction of interleukin 2. Proc Natl Acad Sci U S A 1989;86:2809-13.
36. Zehavi-Willner T, Shalit I. Enhancement of interleukin-2 production in human lymphocytes by two new quinolone derivatives. Lymphokine Res 1989;8:35-46.
37. Shalit I. Immunological aspects of new quinolones. Eur J Clin Microbiol Infect Dis 1991;10:262-6.
38. Kletter Y, Riklis I, Shalit I, Fabian I. Enhanced repopulation of murine hematopoietic organs in sublethally irradiated mice after treatment with ciprofloxacin. Blood 1991;75:1685-91.
39. Riesbeck K, Sigvardsson M, Leanderson T, Forsgren A. Superinduction of cytokine gene transcription by ciprofloxacin. J Immunol 1994;153:343-51.
40. Kletter Y, Singer A, Nagle A, Slavin S, Fabian I. Ciprofloxacin enhances hematopoiesis and peritoneal neutrophil function in lethally irradiated, bone marrow-transplanted mice. Exp Hematol 1994;22:360-5.
41. Riesbeck K, Forsgren A. Selective enhancement of synthesis of IL-2 in lymphocytes in the presence of ciprofloxacin. Eur J Clin Microbiol Infect Dis 1990;9:409-17.
42. Jimenez-Valera M, Sampedro A, Moreno E, Ruiz-Bravo A. Modification of immune response in mice by ciprofloxacin. Antimicrob Agents Chemother 1995;39:150-4.
43. Fishman P, Falach-Vaknin E, Sredni B, Meroni PL, Tincani A, Dicker D, et al. Aspirin-interleukin-3 interrelationships in patients with anti-phospholipid syndrome. Am J Reprod Immunol 1996; 35:80-4.
44. Bruno E, Cooper RJ, Briddell RA, Hoffman R. Further examination of the effects of recombinant cytokines on the proliferation of human megakaryocyte progenitor cells. Blood 1991;77:2339-46.
45. Toder V, Shomer B. The role of lymphokines in pregnancy. Immunol Allergy Clin North Am 1990;10:65-77.
46. Tatakovsky B, Ben-Yair E. Cytokines modulate preimplantation development and pregnancy. Develop Biol 1991;146:345-52.
47. Athanassakis I, Bleackly RC, Paeykau V, Guilbert L, Barr PJ, Wegmann TG. The immunostimulatory effect of T cells and T cell lymphokines on murine fetally derived placental cells. J Immunol 1987;138:37-42.
48. Alala PK, Graham CH. Mechanism of trophoblast invasiveness and their control: the role of proteases and protease inhibitors. Cancer Metastasis Rev 1990;9:369-79.
49. Guilbert LJ, Wegmann TG. The role of cytokines in gestation. Crit Rev Immunol 1994;14:239-92.
50. Wegmann TG, Athanassakis I, Guilbert L, Branch D, Dy M, Maenu E, et al. The role of M-CSF and GM-CSF in fostering placental growth, fetal survival. Transplant Proc 1989;12:566-79.
51. Debil N, Hegyi E, Navarro S, Katz A, Mouthon MA, Breton-Gorius J, Vainchenker W. In vitro effects of hematopoietic growth factors on the proliferation, endoreplication and maturation of human megakaryocytes. Blood 1991;77:2326-38.
52. Torchinsky A, Fein A, Toder V. Immunoteratology. I. MHC involvement in the embryo response to teratogens in mice. Am J Reprod Immunol 1995;34:288-98.
53. Taguchi T Jr, McGhee RL, Coffman KW, Beagley JH, Eldridge K, Takatsu K, et al. Detection of individual splenic T cells producing IFN-gamma and IL-5 using the enzyme linked immunospot (ELISPOT) assay. J Immunol Methods 1990;128:65-73.
54. Berkovitch M, Pastuszak A, Gazarian M, Lewis M, Koren G. Safety of the new quinolones in pregnancy. Obstet Gynecol 1994;84:535-8.
55. Leung D, Venkatesan P, Boswell T, Innes JA, Wood MJ. Treatment of typhoid in pregnancy [letter]. Lancet 1995;346:648.
56. Forsgren A, Schlossman ST, Tedder TF. 4-Quinolone drugs affect cell cycle progression and function of human lymphocytes in vitro. Antimicrob Agents Chemother 1987;31:768-73.
57. Roszkowski W, Ko HL, Roszkowski K, Ciborowski P, Jeljaszewicz J, Pulverer G. Effects of ciprofloxacin on the humoral and cellular immune response in BALB/c-mice. Zentralb Bakteriol 1986;23: 396-402.